ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Organ Systems Program Reorganization Complete; Annual Conferences To Replace Working Groups

May 26, 1989

In Brief: Sondik is Acting NCI Deputy Director; $21 mil. Gift Supports Univ. Of Chicago

March 4, 1994

Clinical Trials Issues: Maryland Law Mandates Insurance Coverage Of Patient Care Costs In Clinical Trials

July 3, 1998

Cancer Information Available By Fax

May 3, 1991

In Brief: President Proposes $1,994 Billion For NCI;

February 10, 1995

In Brief: Simone Named New Director At St. Jude; Schein To Leave Georgetown For Job At Smith-Kline

September 16, 1983